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Introduction
The mucopolysaccharide (MPS) disorders are a group of
lysosomal storage disorders in which the enzymes respon-
sible for the catabolism of glycosaminoglycans (GAGs, pre-
viously known as MPS) are deﬁcient. This deﬁciency results
in the accumulation of GAGs in the cells, blood, and con-
nective tissue of the body and brain. Seven distinct types of
MPS disorders have been identiﬁed associatedwith different
enzyme deﬁciencies and are usually, but not wholly, char-
acterized by a period of normal development followed by
physical and/or cognitive decline and often premature
death.1 MPS I (Hurler syndrome and the less severe variants
of Scheie and Hurler-Scheie syndromes) is particularly asso-
ciatedwith skeletal abnormalities, motor and cognitive delay
and occurs in approximately 1 in 100,000 live births
although, as with all the MPS disorders, international varia-
tion exists.2 MPS II (Hunter syndrome) is associated almost
entirelywithmales and occurs in approximately 1 in 170,000
live births with affected children identiﬁed as having a
severe or mild variant phenotype depending on cognitive
impairment and progression of the disorder.3 MPS III (Sanﬁ-
lippo syndrome) is the most common MPS disorder, occur-
ring in 1 out of 24,000 live births and with four genetically
distinct subtypes (A–D) related to deﬁciencies in speciﬁc
enzymes responsible for the breakdown of heparan sulfate.
Other forms of MPS, including MPS IV (Morquio syndrome),
MPS VI (Maroteaux–Lamy syndrome), MPS VII (Sly syn-
drome), and MPS IX (Natowicz syndrome), are extremely
rare and tend to be associated with physical abnormalities
rather than cognitive impairment.
When examining the clinical implications of the MPS
disorders, researchers and clinicians are primarily concerned
with the behavioral phenotype of a given disorder, which can
be understood as the increased likelihood of speciﬁc beha-
viors being associated with any given disorder.4 Moreover,
many children with MPS show signs of other developmental
disabilities such as autism in MPS III,5 as well as signiﬁcant
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behavioral and emotional difﬁculties as part of their beha-
vioral phenotype,6 the consequences of which are often
exacerbated asmanyclinicians have no knowledge or experi-
ence of the underlying MPS or associated phenotype. Con-
sidering the various MPS disorders, sleep disturbance and
fearfulness are features of thebehavioral phenotypes forMPS
I and MPS II presentation, with relatively normal develop-
ment and few or no behavioral problems in the mild form of
MPS II, while those with the severe form show behavioral
problems, delayed speech, delayed development, and limited
motor function. In contrast, the clinical presentation of MPS
III is very heterogeneous7 with sleep disturbance and fre-
quent behavioral problems relating to aggression, hyperac-
tivity, orality, unusual emotional responses, and temper
tantrums being identiﬁed via systematic review.6 Empirical
studies of the behavioral phenotype for children in the
middle phase (2–9 years) of MPS III8 have subsequently
identiﬁed elevated rates of hyperactivity, orality, bodily
movements, and attentional problems as well as sleep difﬁ-
culties. In contrast, children with MPS IV show distinct
physical features with impaired mobility and speech but
few behavior problems, these being primarily emotional and
attentional9
Sleep and Circadian Rhythm Abnormalities
in Mucopolysaccharidoses
The association between sleep dysfunction and the MPS dis-
orders, and in MPS III in particular, has long been noted by
clinicians.10A systematic review11of sleepdisorders associated
with genetic disorders, including MPS, identiﬁed several stu-
dies using objective assessment such as polysomnography
(PSG) and actigraphy but with mixed samples of children
with MPS. PSG-based studies by Nashed et al and Santamaria
et al12,13withmixedMPS samples of fourMPS IH, twoMPS IHS,
threeMPS II, twoMPS IV,twoMPS IS, threeMPS II, oneMPS IIIB,
four MPS IVA, one MPS VI, respectively, indicated normal sleep
latency (i.e., time to falling asleep) but reduced overall sleep
time. Both of these samples were selected on the basis of pre-
existing sleep-respiratory problems, and further work14 also
utilizing amixed sample (3MPS I, 15MPS II, 1MPS III, 1MPS IV,
4MPSVI) but selectedon thebasis ofMPSdiagnosis rather than
sleep or breathing difﬁculties, and focused on sleep architec-
ture rather than sleep timing, identiﬁed that all children with
MPS showed objective signs of obstructive sleep apnea.
All of the studies described above have used highly
heterogeneous samples of children with MPS without any
form of non-MPS comparison group. Turning to studies using
more homogenic samples, a study15 using 48-hour PSGwith
six children with MPS IIIA only (mean aged 14.1 years), and
compared with age- and sex-matched controls, found impo-
verished total night-time sleep (240.5 minutes versus
458.3 minutes), but increased daytime sleep (88.8 minutes
versus 24.8 minutes) with substantially decreased rapid eye
movement sleep (8.03 versus 21.53%). Overall, the over-
whelming majority of MPS-related sleep research has
focused on MPS III and a wide range of sleep problems,
including bedtime resistance, sleep onset delay, sleep dura-
tion, sleep anxiety, night waking, night behaviors, parasom-
nias, sleep disordered breathing, and daytime sleepiness,
have long been identiﬁed as being part of the clinical pre-
sentation and are now regarded as part of the behavioral
phenotype ofMPS III.16,17 Such sleep disturbancehas amajor
impact on individuals with MPS III and inevitably also on
their families, with parents reporting disruption in their own
sleep patterns and that of siblings.18 Such sleep difﬁculties
are also associated with daytime challenging behavior16 and
there is a trend for sleep difﬁculties, particularly sleep onset
latency and sleep efﬁciency, to worsen with age and disease
progression.17
There is emerging evidence that these sleep problems
may be linked to an underlying disturbance in circadian
functioning inMPS III,17,19,20whichmay also be an inﬂuence
on aggressive behavior and hyperactivity.21 The recent study
by Mahon et al17 utilizing both actigraphy and melatonin
assay reported that children with middle phase MPS III had
higher endogenous melatonin concentrations between 6am
and 8am and lower levels at 10pm—midnight comparedwith
age-matched controls. Moreover, there was effectively no
signiﬁcant differences in melatonin across 24 hours in the
MPS III group, thus demonstrating a signiﬁcantly abnormal
circadian rhythm of melatonin concentration (►Fig. 1). This
has clear implications for sleep function, as reduced levels of
melatonin at night will result in difﬁculties falling asleep,
while elevated levels ofmelatonin in themorning will lead to
an increase in daytime napping.22
Futurework on circadian rhythm inmiddle phaseMPS III21
has examined fragmentationof rhythm(intradaily variability),
stability of rhythm to external zeitgebers (interdaily stability),
time of the “best ﬁt” of circadian cycle (periodicity) and the
onset of the least active 5-hour (L5 onset), andmost active 10-
hour (M10 onset) periods as well as measuring activity levels
across four quadrants of a 24-hour period (midnight—6 am, 6
am—12 pm, 12 pm—6 pm, and 6 pm—midnight). Circadian
rhythms were found to be more fragmented and less stable in
childrenwithmiddle phaseMPS III together with a later onset
of wakefulness and activity and variability in the onset of the
least active period. With regard to activity, childrenwith MPS
III demonstrated increased activity in the earlymorning hours
(midnight–6 am), followed by lower activity between 6 am
and12 pm (►Fig. 2).
Overall, these data corroborate the earlier biochemical
data and are indicative of a possibly unique pattern of
circadian functioning associated with the middle stage of
MPS III. These data have important clinical implications, as
being “out of sync” with both the immediate environment
and the circadian patterns of carers, family and society in
general are likely to have a major impact on quality of life for
children with MPS III and their families.
Clinical Implications of Circadian and Sleep
Abnormalities in MPS III
Given the clinical and research evidence reviewed above, it is
strongly recommended that at least all children with MPS III
shouldbe investigated forbothsleepandcircadiandisturbance
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as soon as possible after initial diagnosis and as part of the
routine clinical management of the condition. In particular,
both actigraphic assessment and melatonin assays have been
showntobefeasible forchildrenwithMPS III to tolerate and for
their families to manage.17,21 Moreover, behavioral interven-
tions inparticular have considerable utility formanaging sleep
problems in children with severe developmental disabil-
ities23,24 and it is recommended that following objective sleep
assessment, advice on behavioral modiﬁcation should be
provided to caregivers with a speciﬁc focus on bedtime
resistance, sleep onset difﬁculties, sleep anxiety, night-time
waking, disruptive/dangerous behaviors at night, daytime
sleep and tiredness. In addition, it is important for clinicians
to be aware that sleep disturbance and dysfunction always
affect more than just the child with MPS III and therefore to
offer support for parents and siblings at the same time. With
regard to physical and pharmacological interventions, upper
airway assessment and management are currently recom-
mended in the case of MPS I and MPS IV25,26 and clinicians
should be alert to the possibility of this in the other forms of
MPS. The evidence regarding pharmacological interventions
for sleep disturbance in MPS is more limited, but the use of
melatonin is supported by clinical27 as well as research stu-
dies,17while the use ofmajor tranquilizers with patients with
MPS III is contraindicated given the risk of extrapyramidal
symptoms.28 In addition to the speciﬁc issues identiﬁed for
MPS I, III, and IV, it is also important forclinicians tobeawareof
that sleepdysfunction is also reported, albeit toa lesserdegree,
in other forms of MPS and that it would be advisable to
routinely assess sleep in the course of ongoing clinical
management.
A further implication of the recent research into sleep and
circadian rhythm dysfunction in MPS III is the possibility of
these forming part of the outcome variables in treatment
trials, themore so given the very robust nature of actigraphic
and melatonin assay data.
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